An Organotypic Model of the Brain & Blood Brain Barrier
Our advanced model of the brain and blood brain barrier represents a significant step forward in the study of neurological disorders and potential therapeutic interventions. This approach enables 3D neural circuit formation and a better understanding of cell-cell and cell-matrix interactions. It allows us to simulate the complex and dynamic environment of the brain, providing a comprehensive testing environment for potential therapeutic interventions.
Modelling the blood brain barrier allows us to study neuroinflammation which is a potential therapeutic target for a wide range of neurological disorders including Alzheimer’s disease, Parkinson’s disease and multiple sclerosis.
Our brain model is particularly useful for disease modelling, drug screening, and neurotoxicity studies. We are using our model to validate potential drug candidates and test their safety and efficacy in a highly controlled setting thus providing a more accurate and predictive testing environment than traditional in vitro and animal models.
More Advanced Neurotoxicity Screening
Neurotoxicity assays are vital in predicting drug safety, particularly in the development of chemotherapy drugs, where drug-induced toxicity can have severe and lasting effects on patient health.
Our brain model permits screening for neurotoxicity, an essential factor in predicting drug safety. Our validated neurotoxicity assay provides crucial data on cell viability and neurite outgrowth in response to known neurotoxins.
By utilizing our brain model for neurotoxicity screening, we can improve the accuracy and safety of drug development, providing a more efficient and sustainable option for drug discovery than existing methods. This technology will enable us to accelerate the development of potential drug candidates.
A Clinically Relevant Model of Parkinson’s Disease
Parkinson’s disease is a progressive neurological disorder that affects millions of people worldwide. Its prevalence is increasing as the population ages. To better understand the complex nature of Parkinson’s disease, we have developed a clinically relevant model that expresses key biomarkers and reproduces the features of neurodegeneration and neuroinflammation.
Our model enables us to study the complex nature of Parkinson’s disease. By reproducing the features of neurodegeneration and neuroinflammation, we can better understand the mechanisms of the disease and identify key targets for drug discovery. Our model also expresses the key biomarkers of Parkinson’s disease allowing us to identify potential drug candidates that target these specific pathways. This approach enables us to develop a more accurate and predictive testing environment for potential therapeutic interventions, improving the safety and efficacy of drug development.
Overall, our approach to developing a clinically relevant model of Parkinson’s disease is a significant step forward in the study of neurological disorders and potential therapeutic interventions. This is partcularly urgent as the global prevalence of Parkinson’s disease continues to rise.
